ImmunOs Therapeutics has closed an oversubscribed Series B financing round totaling USD 74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL
ImmunOs Therapeutics has closed an oversubscribed Series B financing round totaling USD 74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL